|
|
|
|
|
Highlights from the 2022 European Society of Medical Oncology Annual Meeting |
|
|
|
|
|
Proffered Paper Session 1: GU Tumors, Non-Prostate
|
|
| IMmotion010: Efficacy and Safety from the Phase III Study of Atezolizumab vs Placebo as Adjuvant Therapy in Patients with RCC at Increased Risk of Recurrence After Resection
|
| Axel Bex, MD, Ph.D.
|
| In this presentation, Axel Bex discusses the results of the IMmotion010 trial assessing efficacy and safety of atezolizumab vs placebo as adjuvant therapy in patients with RCC at increased risk of recurrence after resection. · Atezolizumab as adjuvant therapy after resection for patients with RCC with increased risk of recurrence did not improve clinical outcomes vs placebo in the ITT population.
|
|
|
|
|
|
| Phase III RandOmized Study Comparing PErioperative Nivolumab versus Observation in Patients with RCC Undergoing Nephrectomy (PROSPER, ECOG-ACRIN EA8143), a National Clinical Trials Network trial
|
| Mohamad Allaf, MD
|
| Mohamad Allaf discussed the results of the phase 3 open label PROSPER trial assessing perioperative nivolumab versus observation in patients with RCC undergoing nephrectomy. Specifically, this trial examined the effect of priming the immune system with neoadjuvant nivolumab prior to nephrectomy followed by adjuvant nivolumab in patients with high risk RCC compared to surgery alone.
|
|
|
|
|
|
| Do the Results of the Perioperative Renal Cancer Trials Make Any Sense?
|
| Thomas B. Powles, MBBS, MRCP, MD
|
| The 2022 ESMO meeting featured a kidney cancer session, including a discussant presentation by Dr. Tom Powles discussing two key abstracts including “IMmotion010: efficacy and safety from the Phase III study of atezolizumab vs placebo as adjuvant therapy in patients with renal cell carcinoma (RCC) at increased risk of recurrence after resection” presented by Dr. Axel Bex, and “Phase III RandOmized Study Comparing PErioperative Nivolumab versus Observation in Patients with RCC Undergoing Nephrectomy (PROSPER, ECOG-ACRIN EA8143), a National Clinical Trials Network trial” presented by Dr. Mohamad Allaf.
|
|
|
|
|
|
|
|
|
|
|
| PD-L1 Expression on Immune Cells by SP142 Co-Localizes with Dendritic Cells and Is Associated with Improved OS with Atezolizumab in Patients with Untreated Metastatic Urothelial Cancer
|
| Enrique Pulido, MD, Ph.D.
|
| Enrique Pulido discussed outcomes of PD-L1 expression on immune cells by SP142 in patients treated with atezolizumab for untreated metastatic urothelial cancer. This IMvigor130 exploratory analysis showed that SP142 PD-L1 staining preferentially co-localized with dendritic cells compared with other myeloid subsets.
|
|
|
|
|
|
| Genomic Biomarkers in Peripheral Blood from Patients Enrolled in the JAVELIN Bladder 100 Trial of Avelumab First-Line Maintenance in Advanced Urothelial Carcinoma |
| Thomas Powles, MBBS, MRCP, MD |
| Tom Powles discussed genomic biomarkers in peripheral blood from patients enrolled in the JAVELIN Bladder 100 trial of avelumab first-line maintenance in advanced urothelial carcinoma. Chromatin conformation signatures affecting the ability to form tertiary lymphoid structures may influence response to avelumab at low tumor mutation burden. |
|
|
|
|
|
| Biomarkers for Advanced Urothelial Carcinoma: Are We There Yet?
|
| Rana McKay, MD
|
| The 2022 ESMO annual meeting featured a urothelial carcinoma session, including a discussant presentation by Dr. Rana McKay discussing biomarkers for advanced urothelial carcinoma. Dr. McKay discusses two abstracts: “Genomic biomarkers in peripheral blood from patients enrolled in the JAVELIN Bladder 100 trial of avelumab first-line maintenance in advanced urothelial carcinoma” presented by Dr. Tom Powles and “PD-L1 expression on immune cells by SP142 co-localizes with dendritic cells and is associated with improved OS with atezolizumab in patients with untreated metastatic urothelial cancer” presented by Dr. Enrique G. Pulido.
|
|
|
|
|
|
|
